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Abstract  
Although PARP inhibitors target BRCA1 or BRCA2 mutant tumour cells, drug 
resistance is a problem. PARP inhibitor resistance is sometimes associated 
with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. 
Whether secondary mutant tumour cells are selected for in a Darwinian 
fashion by treatment is unclear. Furthermore, how PARP inhibitor resistance 
might be therapeutically targeted is also poorly understood. Using CRISPR-
mutagenesis, we generated isogenic tumour cell models with secondary 
BRCA1 or BRCA2 mutations. Using these in heterogeneous in vitro culture or 
in vivo xenograft experiments where the clonal composition of tumour cell 
populations in response to therapy was monitored, we established that PARP 
inhibitor or platinum salt exposure selects for secondary mutant clones in a 
Darwinian fashion, with the periodicity of PARP inhibitor administration and 
the pre-treatment frequency of secondary mutant tumour cells influencing the 
eventual clonal composition of the tumour cell population. In xenograft studies 
the presence of secondary mutant cells in tumours impaired the therapeutic 
effect of a clinical PARP inhibitor. However, we found that both PARP inhibitor 
sensitive and PARP inhibitor resistant BRCA2 mutant tumour cells were 
sensitive to AZD-1775, a WEE1 kinase inhibitor. In mice carrying 
heterogeneous tumours, AZD-1775 delivered a greater therapeutic benefit 
than olaparib treatment. This suggests that despite the restoration of some 
BRCA1 or BRCA2 gene function in “revertant” tumour cells, vulnerabilities still 
exist that could be therapeutically exploited.  
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Introduction  
Heterozygous germ-line mutations in the BRCA1 or BRCA2 tumour 
suppressor genes strongly predispose to cancers of the breast, ovary, 
pancreas, and prostate (1,2). BRCA1 and BRCA2 are involved in homologous 
recombination (HR), a process used to repair DNA double-strand breaks 
(DSBs), and other DNA lesions that impair replication forks (3-6).  Extensive 
preclinical and clinical data has established that loss of BRCA1 or BRCA2 
function is associated with sensitivity to small molecule PARP inhibitors (7). 
Recently, the PARP inhibitor (PARPi) Lynparza (olaparib/AZD2281 – 
KuDOS/AstraZeneca) was approved for the treatment of platinum-responsive, 
BRCA1 or BRCA2 mutant high-grade serous ovarian carcinomas (HGSOC) 
(8). 
 
Despite a number of profound and sustained anti-tumour responses in 
patients treated with PARP inhibitors, drug resistance limits the overall 
effectiveness of these agents (9-12). A number of mechanisms of PARP 
inhibitor resistance have been identified, including upregulation of PgP drug 
transporters, loss of 53BP1 or REV7 function, or secondary “revertant” 
mutations within the BRCA1 or BRCA2 genes themselves (13,14). These 
secondary BRCA gene mutations restore BRCA1 or -2 open reading frames 
and encode proteins that have partial function (13-16). In some BRCA2 
mutant patients, initial clinical responses to PARPi are seen, followed by the 
emergence of profoundly PARPi resistant lesions (13). The gradual 
emergence of PARPi resistance during treatment has led to the hypothesis 
that PARPi treatment might provide a Darwinian selective pressure effect, 
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where a secondary mutant clone has a selective advantage over non-
secondary mutant tumour clones, once PARPi treatment is applied (7,17). 
Although this hypothesis has not as yet been tested, if such a Darwinian 
process did exist, a secondary mutant clone might be expected to gradually 
dominate a tumour cell population over the course of PARPi therapy. To date, 
only one approach for targeting tumour cell clones with secondary BRCA1/2 
mutations has been proposed, namely the use of thiopurines (18). The wide 
application of thiopurines in the treatment of cancer has been limited by safety 
concerns (18), suggesting that additional therapeutic approaches for targeting 
secondary BRCA1/2 mutant tumour cells might also be required.  
 
We set out to assess, both in vitro and in vivo, whether tumour cells with 
secondary BRCA1 or -2 gene mutations are selected for by PARPi treatment 
in a Darwinian fashion. To do this, we used CRISPR-Cas9 mediated gene 
targeting in BRCA1 or BRCA2 mutant tumour cells to generate daughter 
clones with secondary mutations. By mixing these secondary mutant clones 
with parental tumour cells in in vitro co-cultures or in vivo tumour xenografts, 
we established that PARPi treatment can select for secondary mutant clones 
in a Darwinian fashion. Using these same systems, we also found that 
exposure to a clinical WEE1 kinase inhibitor (AZD-1775) minimized the 
selection of secondary mutant tumour cells, targeting parental and secondary 
mutant cells to a similar extent, whilst having minimal effects on non-tumour 
cells.  
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Materials and Methods 
 
Cell lines 
CAPAN1 and SUM149 cells were obtained from American Type Tissue 
Collection. DLD1-BRCA2WT/WT and DLD1-BRCA2–/– cells were purchased 
from Horizon Discovery Inc. All cells were cultured according to the supplier’s 
instructions. All cells were STR typed to confirm identity and verified to be 
mycoplasma-free prior to the study.  
 
Small molecule inhibitors 
Olaparib, talazoparib, and AZD-1775 were obtained from Selleck Chemicals. 
Inhibitor stock solutions were prepared in DMSO and stored in aliquots at 
minus 20°C. Inhibitors were added to cell cultures so that final DMSO 
concentrations were constant at 1% (v/v). 
 
CRISPR-generated PARPi-resistant secondary mutant cell lines 
CAPAN1.B2.S* and SUM149.B1.S* were generated from CAPAN1 and 
SUM149 parental tumour cell lines. Parental lines were transiently transfected 
with 5 g of gRNA (described below) and 5 g of a Cas9 pMA-T expression 
vector (GE Healthcare) using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. Twenty-four hours later, cells were re-plated 
into 15 cm dishes at 2000 cells/dish and exposed to 100 nM talazoparib for 
two weeks after which clones were cultured in talazoparib free media until 
visible. Clones were manually isolated, and re-plated into 96-well plates for 
expansion. DNA from clones was isolated using DNeasy Blood and Tissue Kit 
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(Qiagen) and PCR amplified using BRCA1 or BRCA2 primers described 
below. PCR products were subcloned using TOPO TA Cloning Kit, with 
pCR2.1-TOPO (Invitrogen). Sanger sequencing confirmed secondary BRCA1 
or BRCA2 mutations from 20 subcloned E.coli colony sequences per cell line. 
 
gRNA (in pMA-T vector): BRCA2, 5-GAGCAAGGGAAAATCTGTCC-3 and 
BRCA1, 5-CCAAAGATCTCATGTTAAG-3. The BRCA2 gRNA contains the 
c.6174delT mutation specific to the CAPAN1 cell line.  
 
Primers for PCR amplification were: BRCA1, 5-
TGCTTTCAAAACGAAAGCTG-3, 5-ACCCAGAGTGGGCAGAGAA-3; 
BRCA2, 5-CTGTCAGTTCATCATCTTCC-3, 5-
ATGCAGCCATTAAATTGTCC-3. 
 
 
Confocal microscopy 
Cells on glass coverslips were exposed to 5 Gy IR using an X-ray machine 
and then fixed and stained 5 hours later as described previously (19). Nuclei 
were stained using DAPI diluted in PBS (1:10,000 v/v), RAD51 using the 
Abcam (ab137323) antibody and H2Ax using the Millipore (05-636) antibody. 
At least 100 cells were assessed per coverslip. Cells scoring positive had > 5 
foci per nucleus. 
 
Immunoprecipitation (IP) and Western Blotting 
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IP and western blotting were performed as described previously (15,20). 
Antibodies targeting phospho-CDC(Y15) (#4539), PARP1 (#9542), -H2AX 
(#9718) (all Cell Signalling Technology), and tubulin (#T6074, Sigma) were 
employed in western blots.  
 
Cell-based Assays 
Short-term drug exposure and clonogenic assays were performed as 
described previously (21). In brief, cells were seeded either into 384-well or 6-
well plates at a concentration of 500 to 2,000 cells per well. After 24 hours, 
cells were exposed to olaparib, talazoparib, or AZD-1775. For short-term drug 
exposure, cell viability was assessed after five days of drug exposure using 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) as per the 
manufacturer's instructions. For clonogenic assays, drug was replenished 
every three days for up to 14 days, at which point colonies were fixed with 
TCA and stained with sulforhodamine B. Colonies were counted and surviving 
fractions calculated by normalizing colony counts to colony numbers in 
vehicle-treated wells. Survival curves were plotted using a four-parameter 
logistic regression curve fit as described in (22). 
 
In vitro co-culture drug exposure assays  
Cells were plated in a fixed starting ratio of secondary mutant:parental cells in 
either 24 well or 6 well plates, or T75 flasks and exposed to either olaparib, 
talazoparib, or AZD-1775 for 14 or 21 days. In “constant drug exposure” 
experiments, media containing drug was replenished every three days. In 
“intermittent drug exposure” experiments, cells were exposed to media 
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containing drug for 24 hours after which, media was removed, cells were 
washed using PBS and then cells were re-cultured in media without drug for 
48 hours, at which point cells were “refed” with media containing drugs as 
before.  
 
DLD1 drug exposure assay 
DLD1-BRCA2WT-GFP and DLD1- BRCA2–/–-RFP cells were plated at one of 
the following ratios: 1:1, 1:10, 1:100, or 1:1000. Twenty-four hours later, cells 
were exposed to DMSO, olaparib, or talazoparib.  Aliquots of cell populations 
were analysed by flow cytometry, every 3-4 days, (LSR II, Beckman-Coulter) 
for GFP and RFP cell populations. Drug was replenished every three days. 
 
Droplet digital PCR (ddPCR) Assays 
Cells were pelleted and genomic DNA was extracted using the DNeasy Blood 
and Tissue Kit (Qiagen) following the manufacturer’s instructions. DNA 
concentration was measured using Qubit broad range detection kit 
(Invitrogen). Restriction digestion was performed with EcoRI (BD Biosciences) 
and final working dilutions were made at 5 g/uL per sample. DNA reaction 
mixtures were performed as described previously (23).  
Primers and probes were as follows: 
CAPAN1  
ddPCR PROBE: VIC-CTGGACAGATTTTC,  
FORWARD PRIMER: 5’- TCTCATCTGCAAATACTTGTGGGATT-3’ 
REVERSE PRIMER: 5’- TTGTCTTGCGTTTTGTAATGAAGCA-3’  
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CAPAN1.B2.S* 
ddPCR PROBE:  6FAM- CTGATACCTGATTTTC 
FORWARD PRIMER: 5’- TCTCATCTGCAAATACTTGTGGGATT -3’ 
REVERSE PRIMER: 5’- TTGTCTTGCGTTTTGTAATGAAGCA -3’ 
SUM149 
ddPCR PROBE: VIC- TTTGTCAACCTAGCCTTCCA 
FORWARD PRIMER: 5’- TGACAGCGATACTTTCCCAGA -3’ 
REVERSE PRIMER: 5’- GAGATCTTTGGGGTCTTCAGC -3’ 
SUM149.B1.S* 
ddPCR PROBE: 6FAM-ACCAGGTGCATTTGTTAACTTCA 
FORWARD PRIMER: 5’- TGACAGCGATACTTTCCCAGA -3’ 
REVERSE PRIMER: 5’- GCAAAACCCTTTCTCCACTTACT -3’ 
 
AZD-1775 sensitivity assessment 
One hundred forty-six cancer cell lines were profiled as described previously 
(21,24). In brief, cells were plated at a density of 250 or 500 cells per well. 
Twenty-four hours later, media containing WEE1 inhibitor was added to 
adherent cells. After five days of drug exposure, cell viability was measured 
using CellTitre-Glo (Promega). Luminescence data was log2 transformed and 
centered according to the plate median value. Surviving fractions were 
calculated relative to the DMSO-exposed control wells to generate AUC data.   
 
Xenograft experiments 
Female BALB/c nude mice aged 4-6 weeks and 15-22 g in weight (Charles 
River Laboratories) were inoculated subcutaneously with 5x106 tumour cells 
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into the right flank. When tumours reached 100 mm3, six animals from each 
cohort were sacrificed as sentinels to enable estimation of parental and 
secondary mutant tumour cell frequencies prior to treatment. Remaining 
animals were randomized into different treatment arms (n=6) as described in 
the main text. Mice were weighed once weekly; tumours were measured twice 
weekly. When tumours reached 1500 mm3, tumours were harvested and half 
of the tissue was formalin fixed, the other half was snap frozen in liquid 
nitrogen for DNA isolation.  
 
Cell cycle analysis 
 
Asynchronously growing CAPAN1 and CAPAN1.B2.S* cells were plated in 10 
cm dishes (5x105 cells/plate) and treated with 1 µM AZD-1775 or DMSO for 
72 hours. The cells were pulse labelled with 30 µM BrdU (Sigma, B5002) for 1 
hour prior to collection. Cells were harvested using trypsin, washed with PBS, 
fixed in cold 70% ethanol and stored at -20oC overnight. Samples were 
washed with 2 M NaCl/0.5% Triton X-100 and incubated for 30 minutes at 
room temperature. Cell pellets were resuspended in 0.1 M sodium tetraborate 
for 2 minutes and subsequent cell pellets were incubated at room temperature 
for 1 hour in anti-BrdU antibody (BD Biosciences, 347580) diluted in 0.5% 
TWEEN-20/1%BSA/PBS (1 µg antibody per 1 million cells). Sample pellets 
were washed in PBS/1% BSA. Cells were then incubated for 30 minutes at 
room temperature with goat anti-mouse IgG FITC antibody (Sigma, F0257) 
diluted in 0.5% TWEEN-20/1%BSA/PBS (1 µg antibody per 1 million cells). 
Cells were pelleted and resuspended in PBS containing 10 µg/ml RNaseA 
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(Sigma, R4642) and 20 µg/ml propidium iodide (Sigma, P-4170) and 
incubated at room temperature for 30 minutes. Cell cycle analysis was 
performed on a FACS LSR II and analysed using FlowJo software (FlowJo, 
USA). 
 
 
Results 
 
Generation of PARP inhibitor-resistant models harbouring secondary 
BRCA1 or BRCA2 mutations 
We used CRISPR-Cas9 mediated gene targeting to generate novel tumour 
cell models with secondary mutations in either BRCA1 or BRCA2 and then 
used these in in vitro and in vivo co-culture systems to assess the clonal 
evolution of tumour cell populations in response to therapy (Figure 1A). To 
generate these models we used two PARP inhibitor sensitive tumour cell 
lines, the pancreatic ductal adenocarcinoma tumour cell line, CAPAN1 
(BRCA2 mutation c.6174delT, p.S1982fs*22) (13,15,25), and the breast 
tumour cell line SUM149 (BRCA1 mutant c.2288delT, p.N723fsX13) (26). We 
designed specific CRISPR guide RNA (gRNA) expression constructs targeting 
PAM (protospacer adjacent motifs) sequences close to either the BRCA2 
c.6174delT mutation in CAPAN1 cells or the BRCA1 c.2288delT mutation in 
SUM149 cells, and transiently transfected these into cells, alongside a Cas9 
expression construct. We reasoned that the error-prone repair of DSBs in 
these BRCA-gene defective tumour cell lines would in some cells cause 
frameshift secondary mutations in either BRCA1 or BRCA2 that restored the 
open reading frame. In a CAPAN1-derived daughter cell clone, 
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CAPAN1.B2.S*, we identified a five base pair (bp) BRCA2 secondary 
mutation, c.[6174delT;6182del5], in addition to the parental c.6174delT 
mutation (c.6174delT : c.[6174delT;6182del5] allele ratio of 3:2) (Figure 1B, 
Table 1). The BRCA2 c.[6174delT;6182del5] secondary mutation in 
CAPAN1.B2.S* was predicted to restore the open reading frame of the gene 
and to encode a 3612 amino acid (aa) BRCA2 protein (Figure 1C), confirmed 
by western blotting (Supplementary Figure 1A). The secondary mutation in 
CAPAN1.B2.S* was associated with olaparib and also talazoparib resistance 
(Figure 1D and Supplementary Figure 1B, ANOVA p<0.0001) and the ability 
to form nuclear RAD51 foci in response to ionising radiation (Student’s t-test 
p<0.001, Figure 1E, 1F, Supplementary Figure 1C), a biomarker of functional 
DNA repair by BRCA2. The CAPAN1.B2.S* clone also exhibited a similar 
doubling time to the parental CAPAN1 clone, of 2.5 days (Supplementary 
Figure 1D). Using the same approach, we also identified other CAPAN1 
daughter clones with secondary mutations, including CAPAN1.B2.S*2, which 
had three different BRCA2 alleles (BRCA2 c.[6174delT;6185del5], BRCA2 
c.[6174delT;6183delG], and BRCA2 c.[6174delT;6184delTC]) and 
CAPAN1.B2.S*3, which also had three different BRCA2 alleles (BRCA2 
c.[6174delT;6183del6], BRCA2 c.[6174delT;6183del5], and BRCA2 
c.[6174delT;6185del3]) (Supplementary Table 1).              
 
Using a similar approach in SUM149 cells, we identified SUM149.B1.S*, a 
daughter clone which possessed a secondary mutation (an 80-bp BRCA1 
deletion, c.[2288delT;2293del80]), as well as the parental c.2288delT 
mutation (c.2288delT : c.[2288delT;2293del80] alleles in a 1:2 ratio) (Figure 
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1G, Table 1)). This secondary mutation was predicted to restore the open 
reading frame in the parental BRCA1 c.2288delT allele and to encode an 
1836 aa BRCA1 protein (Figure 1H, Supplementary Figure 2A). 
SUM149.B1.S* exhibited both olaparib and talazoparib resistance (Figure 1I, 
Supplementary Figure 2B, ANOVA p<0.0001), and restoration of RAD51 
nuclear localisation in response to DNA damage (Figure 1J, Supplementary 
Figure 2C, Supplementary Figure 2D, p<0.01, Student’s t test). SUM149 and 
SUM149.B1.S* cells exhibited similar proliferation rates (Supplementary 
Figure 2E). 
 
Darwinian selection of BRCA1- or BRCA2-proficient clones by PARPi 
treatment in vitro 
To assess whether a Darwinian selective process might operate in the case of 
PARPi resistance, we mixed parental and secondary mutant tumour cells in in 
vitro co-cultures (i.e. CAPAN1 parental with CAPAN1.B2.S* secondary mutant 
cells, or SUM149 with SUM149.B1.S* cells) and then exposed the co-cultures 
to two different BRCA-gene selective drugs, olaparib or the platinum salt 
cisplatin (Figure 2A). We then monitored the relative frequency of each clone 
in response to drug exposure using droplet digital PCR (ddPCR) (27). To do 
this, we used duplex PCR reactions that included fluorophore-labelled digital 
PCR probes that were complementary to either parental or secondary mutant 
alleles (Supplementary Table 2, see methods). In pilot experiments where we 
mixed CAPAN1 and CAPAN1B2.S* cells in 1:1, 1:10, 1:100 ratios, we were 
able to accurately detect these different ratios using the ddPCR assay 
(Supplementary Figure 3). Using this ddPCR approach, we assessed whether 
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olaparib or cisplatin exposure would preferentially select for the secondary 
mutant clones in either CAPAN1 plus CAPAN1B2.S* co-cultures or SUM149 
plus SUM149.B1.S* co-cultures. In these experiments we exposed co-
cultures to either: (i) DMSO (the drug vehicle), (ii) constant exposure to 
olaparib (drug replenished every three days), (iii) intermittent exposure to 
olaparib (where drug was applied for 24 hours then washed out and 
replenished with media not containing drug for 48 hours), (iv) constant 
exposure to cisplatin (drug replenished every three days), or (v) intermittent 
24 hour pulses of cisplatin (where drug was applied for 24 hours then washed 
out and replenished with media not containing drug for 48 hours)  (Figure 2A). 
As expected, in both CAPAN1 and SUM149 co-cultures, constant exposure to 
either olaparib or cisplatin caused a greater reduction in the total tumour cell 
population size than intermittent drug exposure (Figure 2B). For example, in 
the CAPAN1 co-culture, 37% of the cell population survived after 14 days 
when exposed to constant olaparib, compared to 55% when intermittent drug 
exposure was used (Figure 2B). Despite these reductions in population size, 
both olaparib and cisplatin exposure caused an increase in the relative 
frequency of the secondary mutant clones compared to the parental clone 
(Figure 2C), effects replicated when mixed cultures were exposed to a 
chemically distinct PARP inhibitor, talazoparib (Supplementary Figure 4A). 
We found that the enrichment in the secondary mutant clones compared to 
the parental clones was most profound when cultures were constantly 
exposed to either olaparib or cisplatin, compared to intermittent drug 
exposures (Figure 2C). In cultures exposed to the drug vehicle, the proportion 
of CAPAN1.B2.S* and SUM149.B1.S* in DMSO exposed cultures remained 
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the same throughout the experiment (1:20 secondary mutant:parental clone, 
Supplementary Figure 4B). We therefore concluded that whilst constant drug 
exposure elicited a more profound reduction in the size of the tumour cell 
population, it did enrich for secondary mutant clones. 
 
We then assessed whether the initial frequency of a secondary mutant clone 
in a tumour cell population might influence the time taken for this clone to 
dominate the population when it was exposed to the selective pressure of 
PARP inhibitor therapy. To do this, we generated CAPAN1.B2.S* : CAPAN1 
mixed in vitro cultures with 1:1, 1:20, and 1:40 clone ratios and then exposed 
these to olaparib. We then estimated the temporal evolution of the culture in 
response to drug treatment by using ddPCR to measure CAPAN1.B2.S* : 
CAPAN1 ratios over time (Figure 2D). We found that in each culture, olaparib 
exposure caused an increase in the frequency of the secondary mutant clone 
compared to DMSO exposed cultures, with the fraction of CAPAN1.B2.S* 
cells in each PARPi exposed culture gradually increasing over time (Figure 
2D). We also found that the initial frequency of the secondary mutant clone 
prior to drug treatment influenced the ability of the secondary mutant clone to 
eventually dominate the population (i.e. >75% of the cell population) once 
cells were exposed to PARP inhibitor, as might be expected of a Darwinian 
process (Figure 2D, compare 1:1, 1:20 and 1:40 ratio cultures).  
 
We also used a different model system, isogenic DLD1 tumour cell lines with 
or without targeted mutations in BRCA2 (DLD1.BRCA2WT/WT and 
DLD1.BRCA2–/– (28,29), to validate these observations. We labelled 
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DLD1.BRCA2WT/WT cells with a green fluorescent protein (GFP) and 
DLD1.BRCA2–/– cells with a red fluorescent protein (RFP) marker to enable 
detection and monitoring of co-culture populations via FACS (Supplementary 
Figure 5A). We found that in the absence of drug exposure, the 
DLD1.BRCA2WT/WT cells exhibited a selective advantage over DLD1.BRCA2–/–
cells, as previously shown (28) (Supplemental Figure 5B), and that these cells 
exhibit more than a 10-fold difference in olaparib sensitivity (Figure 3A). We 
then mixed DLD1.BRCA2WT/WT cells into DLD1.BRCA2–/– cells in vitro at 
starting ratios of 1:1, 1:10, 1:100 and 1:1000, exposed these co-cultures to 
either olaparib or talazoparib, and monitored the temporal evolution of the 
population in response to PARPi (Supplementary Figure 5A). Similar to the 
CAPAN1 and SUM149 isogenic models, we observed that olaparib and 
talazoparib both selected for DLD1.BRCA2WT/WT cells over DLD1.BRCA2–/– 
cells in a Darwinian fashion (Figure 3B). For example, both olaparib and 
talazoparib exposure resulted in a 3-fold increase in DLD1.BRCA2WT/WT cells 
compared to the DMSO exposed cell population after 13 days of drug 
exposure (Figure 3B). Additionally, we noticed that the time taken for the 
DLD1.BRCA2WT/WT clone to reach clonal dominance was less in cell 
populations that had higher starting proportion of DLD1.BRCA2WT/WT cells 
(Figure 3C, D, E), as observed in the CAPAN1 co-culture model.  
 
Darwinian selection of secondary mutant tumour cells also operates in 
vivo 
We also assessed whether a Darwinian process influenced the in vivo 
response to PARPi treatment. To do this, we generated cohorts of mice 
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bearing subcutaneous xenografts consisting of a mixture of CAPAN1 parental 
and CAPAN1.B2.S* secondary mutant tumour cells (Figure 4A). We found 
that inoculating 5x106 tumour cells at a 1:1 CAPAN1:CAPAN1.B2.S* ratio 
reproducibly generated 100 mm3 xenografts 10 days after innoculation, where 
each clone was present in equal proportion (Figure 4B). When tumours 
reached 100 mm3, tumour bearing mice were randomised into the following 
treatment cohorts to assess the selective pressure of PARPi treatment in vivo: 
(i) olaparib (50 mg/kg) administered once daily, (ii) olaparib (50 mg/kg) 
administered every other day, (iii) olaparib (50 mg/kg) administered twice a 
week on days 1 and 4, (iv) drug vehicle administered daily. In addition sentinel 
mice were sacrificed prior to treatment so that the CAPAN1:CAPAN1.B2.S* 
ratio in tumours prior to therapy could be confirmed (Figure 4A, 
Supplementary Figure 6A). We found that 50 mg/kg olaparib treatment, 
administered daily, every other day, or twice weekly, though well-tolerated, did 
not decrease tumour growth compared to the vehicle (p > 0.05 ANOVA for 
tumour volume in each olaparib treatment cohort vs. vehicle, Supplementary 
Figure 6B, Supplementary Figure 6C). We hypothesized that the absence of 
overall anti-tumour efficacy in this particular case might be due to failure to 
inhibit the PARPi secondary mutant clone in xenografts. To test this, we 
isolated tumour DNA from olaparib treated mice (after 28 days treatment) and 
assessed the relative ratio of parental vs. secondary mutant clones by 
ddPCR. In mice that received drug vehicle alone, the ratio of parental vs. 
secondary mutant clones remained unchanged at 50 % (data not shown). 
However, in mice that received olaparib treatment, the relative frequency of 
CAPAN1.B2.S* cells increased in response to therapy (Figure 4C). This 
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increase in CAPAN1.B2.S* frequency, in preference to the parental clone, 
was dependent upon the periodicity of PARPi administration, e.g. daily 
administration of olaparib caused the greatest increase in CAPAN1.B2.S* 
enrichment, followed by every other day treatment and then bi-weekly 
administration (Figure 4C, 4D). This suggested that PARPi administration also 
selected for secondary mutant tumour cell clones in vivo and that the degree 
of secondary mutant clone selection was related to the extent of selective 
pressure applied.  
 
AZD-1775, a WEE1 kinase inhibitor, targets both parental and secondary 
BRCA mutant clones in vitro and in vivo 
The co-culture model systems described above allowed us to establish that 
PARPi resistance, when driven by secondary mutations in BRCA1 or BRCA2, 
can operate along Darwinian principles. We also assessed whether we could 
identify therapeutic vulnerabilities that would allow targeting of both parental 
and secondary mutant tumour cell clones as a means to minimise the impact 
of secondary mutation. We assessed whether small molecule WEE1 cell cycle 
checkpoint kinase inhibitors (WEE1i) (30) might have utility in this regard. We 
focused on WEE1 inhibitors for a number of reasons. WEE1 prevents 
premature mitotic entry by phosphorylating and inhibiting cyclin-dependent 
kinases such as Cyclin Dependent Kinase 1 (CDK1) (31,32). This activity is 
particularly critical in tumour cells with p53 pathway defects; p53 defects often 
co-occur with BRCA mutations, and although secondary mutations in 
BRCA1/2 drive PARPi resistance, resistant tumours and cell lines remain p53 
mutant (13). CAPAN1.B2.S* and SUM149.B1.S* clones retained the p53 
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mutations present in CAPAN1 and SUM149 parental tumour cell clones 
(Supplementary Figure 7, Supplementary Figure 8). We also found that in an 
analysis of in vitro sensitivity to the clinical WEE1 kinase inhibitor, AZD-1775, 
in a panel of tumour cell lines, CAPAN1.B2.S* and SUM149.B1.S* were 
amongst the most sensitive of 146 lines profiled (Figure 5A). We confirmed 
this AZD-1775 sensitivity in subsequent clonogenic survival experiments and 
found that, when compared to non-tumour breast epithelial cell lines (MCF10A 
and MCF12A), both CAPAN1 and SUM149-derived secondary mutant tumour 
cell clones retained profound sensitivity to AZD-1775 seen in parental tumour 
cells (average 22 fold difference in AUC, p < 0.0001 versus MCF10A or 
MCF12A, ANOVA, Figure 5B). We confirmed these observations using co-
culture systems and found that at SF50 concentrations (concentration required 
to inhibit 50% of cells) of either olaparib or AZD-1775, olaparib exposure 
increased the relative frequency of the secondary mutant clones, but AZD-
1775 did not (Figure 5C). This observation was confirmed when we used 
ddPCR to monitor the frequency of the secondary mutant clone over time in 
co-cultures exposed to AZD-1775 (Figure 5D). We also observed that 
parental and secondary mutant SUM149 and CAPAN1 clones were sensitive 
to additional small molecule cell cycle checkpoint inhibitors including PF-
477736, a CHK1 inhibitor (33), and VX-970, an ATR inhibitor (34) when 
compared to non-tumour epithelial cells (Supplementary Figure 9A, 
Supplementary Figure 9B). This suggested that even when partial BRCA1 or 
BRCA2 protein function was restored by secondary mutation, vulnerability to 
small molecule inhibitors that target cell cycle checkpoints still existed. These 
effects did not appear to represent a relatively non-specific sensitivity to 
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cytotoxic agents in the parental and secondary mutant tumour cells, as these 
did not display an overtly distinct level of sensitivity to paclitaxel, capecitabine 
or gemcitabine when compared to MCF10 or MCF12A cells (Supplementary 
Figure 9C-F).  
 
Previous studies have shown that WEE1 inhibitors cause tumour cell 
cytotoxicity by reducing the extent of CDC2 phosphorylation at Y15 (35). We 
found that in both CAPAN1 and CAPAN1.B2.S* cells, AZD-1775 exposure 
caused a decrease in CDC2 Y15 phosphorylation, an effect that was 
enhanced with prolonged drug exposure (Figure 5E). We noted that AZD-
1775 exposure caused an increase in H2AX phosphorylation (H2AX), a 
biomarker of DNA damage, in both CAPAN1 and secondary mutant 
CAPAN1.B2.S* cells (Figure 5E). This increase in H2AX was commensurate 
with an increase in PARP cleavage, a measure of apoptosis (Figure 5E). 
Using FACS profiling, we found that AZD-1775 exposure had a very similar 
effect on cell cycle fractions in both CAPAN1 and CAPAN1.B2.S* cells, both 
of which demonstrated a profound reduction in the fraction of cells in active S-
phase, with a commensurate increase in the proportion of cells in non-
replicating S (Supplementary Figure 10). In CAPAN1 cells, AZD-1775 
exposure caused a reduction in the active S-phase fraction from 25.9 % to 3.4 
% (with a 3.9 to 52.1 % increase in non-replicating S phase), whilst 
CAPAN1.B2.S* cells showed a reduction in active S from 27.8 % to 4.2 % 
(with a 3.3 to 51.4 % increase in non-replicating S). These observations were 
reminiscent of those seen in H3K36me3-deficient cells, where WEE1 
inhibition also caused a severe reduction in the active S phase fraction (36). 
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This suggested that WEE1 inhibition targeted CAPAN1 cells in S–phase, 
regardless of whether BRCA2 was dysfunctional (as in CAPAN1) or 
somewhat reconstituted by the presence of a secondary BRCA2 mutation (as 
in CAPAN1.B2.S*). 
  
To investigate whether WEE1 inhibitor sensitivity in PARPi sensitive and 
resistant clones also operated in vivo, we assessed the effect of AZD-1775 
treatment on mice bearing mixed CAPAN1/CAPAN1.B2.S* xenografts (each 
clone present at a 1:1 ratio, Figure 5F). Mice with established tumours were 
treated with either AZD-1775, olaparib or drug vehicle. Sentinel mice 
sacrificed prior to treatment showed the CAPAN1:CAPAN1.B2.S* ratio in 
tumours prior to therapy was 1:1 (Figure 5G). We used the time taken for 
tumours to reach 1500 mm3 as a surrogate measure of survival (Figure 5H) 
and found that whilst olaparib treatment had minimal benefit (p=0.86, Log 
ranked Mantel-Cox test compared to vehicle), AZD-1775 treatment led to a 
significant survival benefit (p=0.011 Log ranked Mantel-Cox test compared to 
olaparib) (Figure 5I). Consistent with these observations, ddPCR analysis of 
tumours at the end of treatment showed that olaparib therapy caused a 
relative enrichment in the frequency of the secondary mutant clone (p = 0.058 
compared to vehicle, Student’s t test) whilst AZD-1775 did not (p = 0.43, 
compared to vehicle, Student’s t test) (Figure 5J).  
 
Discussion 
In this study we used CRISPR-generated BRCA1 or BRCA2 secondary 
mutant daughter clones alongside isogenic parental cell lines to demonstrate 
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that PARPi exposure selects for secondary mutant clones in a Darwinian 
manner, both in vitro and in vivo. We found that the extent of selection for 
secondary mutant clones was influenced by the frequency of drug 
administration. In mice bearing tumours comprised of an equal proportion of 
BRCA2 mutant and BRCA2 secondary mutant tumour cells, olaparib had 
minimal effects on tumour growth but did preferentially select for the 
secondary mutant daughter clone over the parental tumour cell.  It would be 
reasonable to infer that high frequencies of secondary mutant cells hinder the 
therapeutic effectiveness of PARP inhibitors. We also found that a WEE1 
inhibitor, AZD-1775, had a greater therapeutic effect on mixed 
parental/secondary mutant tumours than olaparib. This example suggests that 
therapeutic vulnerabilities might still exist in tumours that have a high 
frequency of secondary mutant clones. Our data also suggest that secondary 
mutant and parental tumour cells also show sensitivity to other cell cycle/DNA 
damage repair inhibitors, including CHK1 and ATR inhibitors (Supplementary 
Figure 9). It seems possible that whilst secondary BRCA1 or BRCA2 gene 
mutations restore some HR function, these are unlikely to reverse the 
complex set of genomic rearrangements, aneuploidy and p53 mutations found 
in BRCA1 or BRCA2 mutant tumours prior to treatment (37). We hypothesise 
that it is these latter characteristics that sensitise tumour cells to drugs such 
as WEE1 inhibitors, perhaps explaining why AZD-1775 targeted both parental 
and secondary mutant clones. This hypothesis remains to be tested, but the 
observation that secondary mutant tumour cells are sensitive to AZD-1775 
raises the possibility that therapeutic vulnerabilities still exist in PARPi 
resistant tumours.  
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In clinical studies, the maximum tolerated dose (MTD) for single-agent AZD-
1775 was identified as 225 mg twice per day orally over 2.5 days per week for 
2 weeks per 21-day cycle, a dosing regime sufficient to elicit a number of anti-
tumour responses (38). In our in vivo studies (Figure 5) we used 30 mg/kg 
AZD-1775 twice-daily treatments for the entire duration of the study (150 
days). This treatment approach was well tolerated in mice and based on prior 
mouse-based experiments using this WEE1 inhibitor (39). Nevertheless, it is 
possible that a similar constant dosing approach may not be well-tolerated in 
humans. Subsequent work might assess the potential of using intermittent 
WEE1 inhibitor dosing schedules to assess whether these also elicit a survival 
benefit in experiments similar to those shown in Figure 5. 
 
One implication of this work is that the detection of secondary BRCA1 or 
BRCA2 mutations in patients could be important in influencing the choice of 
therapy. At present, secondary mutations in BRCA1 or BRCA2 can be 
detected by Sanger DNA sequencing (14-16) or by targeted DNA capture and 
deep sequencing (13). Circulating tumour DNA and circulating tumour cells 
might also display some of the secondary BRCA1 or BRCA2 mutations found 
in solid tumours. Detecting secondary mutations in such liquid biopsies might 
allow the early emergence of secondary mutations to be identified as a 
biomarker predicting the eventual clinical manifestation of PARPi resistance. 
One avenue we will now explore is to utilise the in vivo system we have 
described here to assess this possibility. A key quality of the model systems 
described here is that they allow the construction of co-cultures and 
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xenografts where the frequency and identity of secondary mutants is known. 
This will hopefully facilitate experiments that aim to examine further principles 
that govern clonal evolution and influence drug resistance in BRCA1 or 
BRCA2 mutant cancers. Alongside these models, we also note that the first 
patient derived xenograft tumours (PDX) with PARPi resistance-causing 
mutations have been recently described (40). These provide another system 
in which to assess how the clonal structure of tumours evolve in response to 
therapy. The combined use of engineered systems, such as that described 
here, alongside PDX systems will be critical in establishing what factors 
determine the response to treatment, and importantly, what therapeutic 
approaches could be taken to minimise the impact of secondary BRCA1/2 
gene mutations.  
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Figure and Table legends 
Figure 1. Characterization of BRCA1 and BRCA2 secondary mutant, 
PARP-inhibitor resistant clones. 
A. Schematic showing experimental design. SUM149 and CAPAN1 cells were 
transfected with Cas9 and CRISPR gRNA expression constructs targeting 
BRCA1 or BRCA2, respectively, to induce DSB and subsequently create a 
secondary BRCA1 or BRCA2 mutation reinstating the open reading frame.  
B. DNA sequence for CAPAN1.B2.S* showing 5 bp deletion in BRCA2. PAM 
sequence is underlined in blue. 
C. Predicted BRCA2 protein structure for CAPAN1.B2.S*. The predicted 
amino acid length is shown. 
D. Dose-response survival curves for CAPAN1.B2.S* (red) and CAPAN1 
parental cell lines exposed to olaparib (P <0.0001, ANOVA). Error bars 
represent SEM (standard error of the mean) from triplicate experiments. 
E. Representative images for nuclear RAD51 foci formation in CAPAN1 and 
CAPAN1.B2.S* cells following IR exposure. Scale bar = 10 m. 
F. Bar chart illustrating quantitation of nuclear RAD51 foci. Cells containing 
more than five foci were counted as positive. Mean ± SEM for three 
independent experiments are shown. p values were calculated using 
Student’s t test. 
G. DNA sequence for SUM149.B1.S* showing 80 bp deletion in BRCA1. PAM 
sequence is underlined in blue. 
H. Predicted BRCA1 protein structure for SUM149.B1.S*. The predicted 
amino acid length is shown. 
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I. Dose-response survival curves for SUM149.B1.S* (green) and SUM149 
parental cells exposed to olaparib (P <0.0001, ANOVA). Error bars represent 
SEM from triplicate experiments. 
J. Bar chart illustrating quantitation of nuclear RAD51 foci. Cells containing 
more than five foci were counted as positive. Mean ± SEM (standard error of 
the mean) for three independent experiments are shown. p values were 
calculated using Student’s t test. 
 
Figure 2. Olaparib exposure induces Darwinian selection favouring 
secondary BRCA mutants in vitro. 
A. Experimental schematic. Secondary mutant and parental cells were mixed 
at a 1:20 ratio and then exposed to DMSO, olaparib, or cisplatin. After drug 
exposure, populations were analysed for surviving fraction and secondary 
mutant:parental proportions using ddPCR.  
B. Bar graph illustrating the effect of drug exposure on population surviving 
fraction in either CAPAN1.B2.S*:CAPAN1 or SUM149.B1.S*:SUM149 co-
cultures.  
C. Bar graph illustrating the increase in secondary mutant clone frequency 
following 14 days of drug exposure.  
D.  Graphs showing the frequency of CAPAN1B2*S cells in 
CAPAN1/CAPAN1B2* co-cultures exposed to 500 nM olaparib. Clone 
frequency was estimated by ddPCR at the time points shown. Error bars 
represent SEM from three independent measurements. 
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Figure 3. PARPi-induced selectivity operates in BRCA2 isogenic DLD1 
tumour cells. 
A. Dose-response curves illustrating 6-well clonogenic survival data for 
BRCA2 isogenic cells, DLD1.BRCA2WT/WT and DLD1.BRCA2–/–, exposed to 
olaparib over 14 days. Error bars represent SEM from triplicate experiments.  
B. Bar graph illustrating the increase in DLD1.BRCA2WT/WT frequency in a 
1:100 starting DLD1.BRCA2WT/WT:DLD1.BRCA2–/– ratio co-culture following 13 
days of drug exposure.  
C. Bar graph showing starting ratio of DLD1.BRCA2–/– to DLD1.BRCA2WT/WT 
influences time (days) for DLD1.BRCA2WT/WT cells to reach clonal dominance 
(75% of cell population). 
D-E. Graphs showing time required for DLD1.BRCA2WT/WT-GFP to reach 
clonal dominance (75%, dotted line) when exposed to either 25 nM or 100 nM 
of olaparib (D) or 10 nM of talazoparib (E) in DLD1.BRCA2WT/WT 
:DLD1.BRCA2–/– co-cultures.   
 
Figure 4. PARPi-induced Darwinian selection of BRCA proficient tumour 
cells in vivo. 
A. Experimental schematic of mixed CAPAN1:CAPAN1.B2.S* xenografts 
treated with olaparib. 
B. Bar chart illustrating CAPAN-1 (white) and CAPAN1.B2.S* (red) cell 
frequency in tumour xenografts prior to drug treatment. Values shown for 
each animal were derived from three tumour sections with mean ± SEM 
shown. 
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C. Bar graph illustrating the increase in secondary mutant clone frequency in 
tumours following 28-day olaparib treatment (n=6, mean ± SEM shown). p 
values were calculated by Student’s t test. 
D. Correlation between fold increase in the frequency of the secondary mutant 
clone and the periodicity of olaparib administration.  
 
Figure 5. PARPi-resistant, secondary mutant clones and parental tumour 
cells are sensitive to AZD-1775 in vitro and in vivo. 
A. Waterfall plot comparing AUC values collated from a five day exposure to 
AZD-1775 from 146 cancer cell lines.  
B. Dose-response survival curves illustrating 6-well clonogenic survival data 
in CAPAN1, CAPAN1.B2.S*, SUM149, SUM149.B1.S*, MCF-10A and MCF-
12A cells exposed to AZD-1775.     
C. Bar graph illustrating the increase in secondary mutant clone frequency 
following 14 days of drug exposure.  
D. Graph showing the frequency of CAPAN1B2*S cells in 
CAPAN1/CAPAN1B2* co-cultures exposed to AZD-1775. Clone frequency 
was estimated by ddPCR and the time points shown. Error bars represent 
SEM from three independent measurements. This experiment was conducted 
alongside the experiment described in Figure 2D; to allow comparison, the 
response to olaparib and DMSO exposure from Figure 2D is re-plotted here. 
E. Western blot for CAPAN1 and CAPAN1.B2.S* cells lysates probed for 
pCDC2(Y15), -H2AX (a DNA damage marker), and cleaved PARP1 (a 
marker of apoptosis). Tubulin was used as a loading control.  
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F. Experimental schematic of mixed CAPAN1:CAPAN1.B2.S* xenografts 
treated with olaparib or AZD-1775. 
G. Bar chart illustrating CAPAN-1 (white) to CAPAN-1.B2.S* (red) clone ratio 
in in tumour xenografts prior to drug treatment. Values shown from six 
sentinel animals with mean ± SEM shown. 
H. Tumour volume plotted against length of treatment for individual xenografts 
comprised of CAPAN1:CAPAN1.B2.S* mixed tumour cells over 150 days 
(n=18 total, n=6 in each cohort).  
I. Survival curves using maximum tumour size (1500 mm3) as a surrogate for 
survival from the experiment shown in E. 
J. Bar chart showing proportion of CAPAN1.B2.S* tumour cells following 
treatment from the experiment shown in E (n=6, mean ± SEM). P values were 
calculated by Student’s t test. 
 
Supplementary Figure 1.   
A. Western blot of lysates with anti-BRCA2 antibodies show almost full length 
BRCA2 is present in CAPAN1.B2.S*. 
B. Dose-response survival curves for talazoparib for CAPAN1.B2.S* (red) 
compared to the parental cell line (P <0.0001, ANOVA). Error bars represent 
SEM from triplicate experiments. 
C. Bar chart illustrating quantitation of nuclear -H2AX foci. Cells containing 
more than five foci were counted as positive. Mean ± SEM (standard error of 
the mean) for three independent experiments are shown. p values were 
calculated using Student’s t test. 
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D. Fold change in cell count plotted against time in CAPAN1 and 
CAPAN1.B2.S* show isogenic cell lines have similar growth rates. Error bars 
represent SEM from triplicate experiments. 
 
Supplementary Figure 2.   
A. IP followed by western blotting of lysates with anti-BRCA1 antibodies 
showing re-expression of near full-length BRCA1 in SUM149.B1.S*. B, 
BRCA1 IP; IgG, control IP. 
B. Dose-response survival curves for talazoparib for SUM149.B1.S* (green) 
compared to the parental cell line (P <0.0001, ANOVA). Error bars represent 
SEM from triplicate experiments. 
C. Representative images for nuclear RAD51 foci formation in SUM149 and 
SUM149.B1.S* cells following IR exposure. Scale bar = 10 m. 
D. Bar chart illustrating quantitation of nuclear -H2AX foci. Cells containing 
more than five foci were counted as positive. Mean ± SEM (standard error of 
the mean) for three independent experiments are shown. p values were 
calculated using Student’s t test. 
E. Fold change in cell count plotted against time in SUM149 and 
SUM149.B1.S* show isogenic cell lines growth rates. Error bars represent 
SEM from triplicate experiments. 
 
Supplementary Figure 3. Sensitive of ddPCR assay can detect up to 
1:100 secondary mutant to parental tumour cell events. 
ddPCR plots showing droplet populations observed for 1:2, 1:10, or 1:100 
starting ratios of secondary mutant:parental tumour cells with either 
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CAPAN1.B2.S* (blue, FAM amplitude) or CAPAN1 (green, VIC amplitude). 
Key: Black drops- empty droplets, blue- CAPAN1.B2.S* DNA FAM positive 
droplets, green- CAPAN1 DNA VIC positive droplets. 
 
Supplementary Figure 4. Olaparib and talazoparib select for secondary 
mutant tumour cells. 
A. CAPAN1/ CAPAN1.B2.S* or SUM149/ SUM149.B1.S* mixed cultures (1:10 
secondary mutant:parental cell ratio) were exposed to either either 1 μM 
olaparib or 0.1 μM talazoparib for 21 days. The frequency of secondary 
mutant cells was monitored by ddPCR. Graphs show the frequency of 
secondary mutant tumour cells in the population over time. 
B. No fitness discrepancy between parental and secondary mutant clone 
observed for mixed CAPAN-1 or SUM149 co-cultures. Bar graphs showing 
day 1 and day 14 DMSO exposed controls for both CAPAN1 and SUM149 
mixed secondary mutant:parental tumour cell populations. 
 
Supplementary Figure 5.  DLD1.BRCA2WT/WT tumour cells have a fitness 
advantage over DLD1.BRCA2–/– cells in vitro. 
A. Experimental schematic for evaluating mixed cell populations consisting of 
DLD1.BRCA2WT/WT-GFP and DLD1.BRCA2–/–-RFP cells at different starting 
ratios (1:1, 1:10, 1:100, 1:1000) over 40 days. Cells were exposed to either 
olaparib or talazoparib at a low and high dose and periodically monitored by 
FACS analysis.  
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B. Graph showing temporal evaluation of DLD1.BRCA2WT/WT tumour cell 
population within mixed DLD1.BRCA2WT/WT-GFP:DLD1.BRCA2–/–-RFP co-
cultures over 40 days. 
 
Supplementary Figure 6. Olaparib has little efficacy in mixed CAPAN-1 
xenografts.  
A. Bar chart illustrating CAPAN-1 (white) to CAPAN-1.B2.S* (red) ratio in day 
0 (pretreatment control) xenografts (n=6, mean ± SEM). 
B. Tumour response in mixed CAPAN1:CAPAN1.B2.S* xenografts treated for 
28 days with 1) vehicle, 2) olaparib – 50 mg/kg (daily), 3) olaparib – 50 mg/kg 
(every-other-day), and 4) olaparib – 50 mg/kg (2x/weekly) (n=6, mean ± 
SEM). 
C. Tolerability of olaparib treatment in vivo over 28 day exposure (n=6, mean 
± SEM). 
 
Supplementary Figure 7. Exome sequencing of CAPAN-1.B2.S* show 
retention of TP53 mutations. 
A-D. Exome sequencing confirms CAPAN1.B2.S* cells retained same TP53 
mutation (A) and variants (B-D) as observed in the CAPAN1 parental cell line.  
 
Supplementary Figure 8. Exome sequencing of SUM149.B1.S* show 
retention of TP53 mutation. 
A. Exome sequencing confirms SUM149.B1.S* cells retained the same TP53 
mutation as observed in the SUM149 parental cell line.  
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Supplementary Figure 9. BRCA-proficient and -deficient cells exhibit 
sensitivity to additional DNA damaging agents. 
A-B. Five day dose-response survival curves for (A) PF-477736, (B) VX-970, 
(C) Gemcitabine, (D) Paclitaxel, (E) Doxorubicin and (F) Vinorelbine for 
CAPAN1, CAPAN1.B2.S*, SUM149 or SUM149.B1.S* compared to MCF-10A 
and MCF-12A cell lines. Error bars represent SEM from triplicate experiments. 
 
Supplementary Figure 10. AZD-1775 causes an active S phase reduction 
in both CAPAN1 and CAPAN-1.B2.S* cells. 
BrdU and propidium iodide (PI) FACS profiling plots are shown with the 
fraction of cells in each cell cycle phase indicated. CAPAN1 and 
CAPAN1.B2.S* cells were exposed to 1 µM AZD-1775, or DMSO for 72 
hours. Following this, the cell cycle distribution of the cells was assayed by 
BrdU/PI FACS analysis as shown. 
